Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer
Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer
复制标题
DOI：
10.1093/annonc/mdh056
复制
发表时间：
2004-02-01
影响因子：
50.5
通讯作者：
Mori, M
中科院分区：
文献类型：
--
作者：
Mimori, K;Tanaka, Y;Mori, M
背景：通过阵列比较基因组杂交（CGH），先前报道了CYP24（编码维生素D 24-羟化酶）在20q13.2的拷贝数增加，从而确定CYP24是乳腺癌的候选致癌基因。材料和方法：采用半定量RT-PCR法检测42例食管癌组织中CYP24和维生素D受体（VDR）基因的表达。我们用25-羟基维生素D-3 [25(OH)D-3]诱导7株食管癌细胞系的CYP24，并用3-(4,5 -二甲基噻唑-2-y)- 2,5 -二苯基溴化四唑（MTT）测定系统比较细胞生长速率。结果：CYP24低表达组25例总生存率显著高于高表达组17例(P
Background: By using array comparative genomic hybridization (CGH), the increased copy number of CYP24 (which encodes vitamin D 24-hydroxylase) at 20q13.2 was previously reported, leading to the identification of CYP24 as a candidate oncogene in breast cancer. CYP24 leads to abrogate growth control mediated by vitamin D.Materials and methods: We examined CYP24 expression as well as VDR (vitamin D receptor) gene expression in 42 esophageal cancer cases using semi-quantitative RT-PCR assay. We induced CYP24 in seven esophageal cancer cell lines using 25-hydroxyvitamin D-3 [25(OH)D-3] and compared cell growth rate, measured using the 3-(4, 5-dimethylthiazol-2-y)-2, 5-diphenyltetrazolium bromide (MTT) assay system.Results: The overall survival rate was significantly higher in 25 cases of lower CYP24 expression than 17 cases of higher CYP24 expression (P